W. Symmans

发表

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

Kevin C. Dorff, Aaron M. Smalter, Stephen C. Harris, 2010, Nature Biotechnology.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

T. Nielsen, E. Thompson, C. Sotiriou, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions.

W. Symmans, W. Symmans, G. Inghirami, 1995, Human pathology.

Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy.

M. Mathieu, F. André, W. Symmans, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue

L. Pusztai, W. Symmans, C. Hatzis, 2014, Molecular oncology.

Concurrent paclitaxel and radiation therapy for breast cancer.

W. Symmans, P. Danenberg, D. Spicer, 1999, Seminars in radiation oncology.

Transfected neu oncogene induces human prostate cancer metastasis

W. Symmans, Shih-Ming Chang, R. Sikes, 1996, The Prostate.

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

M. Espié, C. Sotiriou, C. Desmedt, 2010, The oncologist.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Michael Hogarth, Lajos Pusztai, Rita Nanda, 2016, The New England journal of medicine.

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.

S. Loi, S. Demaria, S. Adams, 2019 .

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Adrian V. Lee, Gregory L. Wheeler, E. Mardis, 2022, Nature Cancer.

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

Søren Brunak, Benjamin Haibe-Kains, Zoltan Szallasi, 2011, BMC Bioinformatics.

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

W. Woodward, G. Hortobagyi, L. Pusztai, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Yuan Qi, Jie Zhang, Christos Hatzis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

Philippe Dessen, Stefan Michiels, Lajos Pusztai, 2009, Clinical Cancer Research.

Malignant melanoma metastatic to the breast

W. Symmans, J. Cangiarella, R. Shapiro, 1998, Cancer.

Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer

Y. Qi, G. Hortobagyi, L. Pusztai, 2014, Clinical Cancer Research.

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

N. Hylton, L. Pusztai, D. Yee, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.

L. Pusztai, G. Babiera, W. Symmans, 2011, Journal of the National Cancer Institute.

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

Benjamin Haibe-Kains, Zoltan Szallasi, Charles Swanton, 2010, The Lancet. Oncology.

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

W. Symmans, S. Demaria, W. Symmans, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes

W. Symmans, D. Roses, J. Cangiarella, 2000, Cancer.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Which threshold for ER positivity? a retrospective study based on 9639 patients.

G. Hortobagyi, H. Kuerer, K. Hunt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

P. Neven, S. Loi, C. Swanton, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

C. Sotiriou, G. Hortobagyi, L. Pusztai, 2007, Clinical Cancer Research.

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes

Y. Qi, G. Hortobagyi, L. Pusztai, 2012, British Journal of Cancer.

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

F. Bertucci, W. Woodward, W. Symmans, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

K. Hess, G. Hortobagyi, L. Pusztai, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine‐needle aspiration

W. Symmans, W. Symmans, D. Roses, 2000, Cancer.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

L. Pusztai, H. Kuerer, J. Mejia, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

What is the role of cytopathologists in stereotaxic needle biopsy diagnosis of nonpalpable mammographic abnormalities?

G. Newstead, W. Symmans, J. Cangiarella, 2001, Diagnostic Cytopathology.

Mammotome core biopsy for mammary microcalcification

W. Symmans, J. Cangiarella, J. Waisman, 2001, Cancer.

The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification

W. Symmans, W. Symmans, J. Cangiarella, 2000, Journal of surgical oncology.

The Use of Stereotaxic Core Biopsy and Stereotaxic Aspiration Biopsy as Diagnostic Tools in the Evaluation of Mammary Calcification

W. Symmans, W. Symmans, J. Cangiarella, 2000, The breast journal.

Reproducibility of Gene Expression Signature–Based Predictions in Replicate Experiments

Lajos Pusztai, Kenneth R Hess, Mini Kapoor, 2006, Clinical Cancer Research.

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

S Michiels, S Adams, S Loi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification

G. Newstead, W. Symmans, W. Symmans, 1998, Cancer.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015 .

Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers

Tingting Jiang, Christos Hatzis, Lajos Pusztai, 2014, Breast Cancer Research and Treatment.

An international Ki67 reproducibility study.

John M S Bartlett, Mitch Dowsett, Lisa M McShane, 2013, Journal of the National Cancer Institute.

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

Christos Hatzis, Erinn Downs-Kelly, Bruno Sinn, 2015, Modern Pathology.

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

G. Hortobagyi, L. Pusztai, S. Michiels, 2009, Clinical Cancer Research.

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

Todd H. Stokes, Kevin C. Dorff, Aaron M. Smalter, 2010, Nature Biotechnology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Commercialized multigene predictors of clinical outcome for breast cancer.

Christos Hatzis, Lajos Pusztai, G. Hortobagyi, 2008, The oncologist.

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Y. Qi, G. Hortobagyi, L. Pusztai, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.